PL2455104T3 - Bio-funkcjonalizowane reagujące na bodziec rozpuszczalne hydrożele PEG - Google Patents

Bio-funkcjonalizowane reagujące na bodziec rozpuszczalne hydrożele PEG

Info

Publication number
PL2455104T3
PL2455104T3 PL10014788T PL10014788T PL2455104T3 PL 2455104 T3 PL2455104 T3 PL 2455104T3 PL 10014788 T PL10014788 T PL 10014788T PL 10014788 T PL10014788 T PL 10014788T PL 2455104 T3 PL2455104 T3 PL 2455104T3
Authority
PL
Poland
Prior art keywords
hydrogels
bio
dissolvable peg
responsive dissolvable
functionalized stimulus
Prior art date
Application number
PL10014788T
Other languages
English (en)
Inventor
Pascal Tomakidi
Torsten Steinberg
Wilfried Weber
Dougal Laird
Raphael Gübeli
Original Assignee
Univ Freiburg
Univ Freiburg Albert Ludwigs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Freiburg, Univ Freiburg Albert Ludwigs filed Critical Univ Freiburg
Publication of PL2455104T3 publication Critical patent/PL2455104T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063Periodont
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL10014788T 2010-11-19 2010-11-19 Bio-funkcjonalizowane reagujące na bodziec rozpuszczalne hydrożele PEG PL2455104T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10014788.3A EP2455104B1 (en) 2010-11-19 2010-11-19 Bio-functionalized stimulus-responsive dissolvable PEG-hydrogels

Publications (1)

Publication Number Publication Date
PL2455104T3 true PL2455104T3 (pl) 2013-12-31

Family

ID=43708001

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10014788T PL2455104T3 (pl) 2010-11-19 2010-11-19 Bio-funkcjonalizowane reagujące na bodziec rozpuszczalne hydrożele PEG

Country Status (9)

Country Link
US (1) US8980278B2 (pl)
EP (2) EP2455104B1 (pl)
JP (1) JP2013544248A (pl)
CN (1) CN103249433A (pl)
DK (1) DK2455104T3 (pl)
ES (1) ES2423798T3 (pl)
PL (1) PL2455104T3 (pl)
RU (1) RU2013127669A (pl)
WO (1) WO2012065751A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862750B2 (en) 2012-06-11 2018-01-09 University Of Newcastle Upon Tyne Recombinant polypeptide
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
US9993577B2 (en) 2013-07-01 2018-06-12 Trustees Of Boston University Dissolvable hydrogel compositions for wound management and methods of use
AU2014348502B2 (en) 2013-11-15 2019-08-15 Tangible Science, Inc. Contact lens with a hydrophilic layer
EP2878312A1 (en) * 2013-12-02 2015-06-03 Albert-Ludwigs-Universität Freiburg Reversible PEGylation of nanocarriers
EP3084433B1 (en) 2013-12-20 2020-03-18 Roche Diagnostics GmbH Method of immobilizing a cell on a support using compounds comprising a polyethylene glycol moiety
JP6461973B2 (ja) 2013-12-20 2019-01-30 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 2以上の疎水性ドメインおよびpeg部分を含む親水性ドメインを含む化合物の、細胞の安定化のための使用
ES2708360T3 (es) 2013-12-20 2019-04-09 Hoffmann La Roche Compuestos que comprenden uno o más dominios hidrófobos y un dominio hidrófilo que comprende restos de PEG, útiles para unir células
WO2015134589A1 (en) * 2014-03-06 2015-09-11 The Regents Of The University Of California Compositions and methods for measuring cellular mechanical stress
EP3131566B1 (en) 2014-04-15 2022-10-05 The Regents of the University of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
US10023735B2 (en) 2014-08-18 2018-07-17 International Business Machines Corporation 3D printing with PHT/PHA based materials and polymerizable monomers
US9957345B2 (en) 2014-08-18 2018-05-01 International Business Machines Corporation 3D printing with PHT based materials
EP3229851A4 (en) 2014-12-09 2018-08-01 Tangible Science LLC Medical device coating with a biocompatible layer
US9758620B2 (en) 2015-09-03 2017-09-12 International Business Machines Corporation Tailorable viscoelastic properties of PEG-hemiaminal organogel networks
WO2017036533A1 (en) * 2015-09-03 2017-03-09 Ecole Polytechnique Federale De Lausanne (Epfl) Three-dimensional hydrogels for culturing adult epithelial stem cells and organoids
US9873766B2 (en) 2015-11-24 2018-01-23 International Business Machines Corporation Systems chemistry approach to polyhexahydrotriazine polymeric structures
US20190247546A1 (en) * 2016-05-17 2019-08-15 Leibniz-Institut Für Polymerforschung Dresden E.V. Method for forming a functional network of human neuronal and glial cells
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
WO2018102715A1 (en) * 2016-12-02 2018-06-07 Indiana University Research And Technology Corporation Compositions and methods for treating and/or reducing corneal dystrophy
CN106754673A (zh) * 2016-12-09 2017-05-31 北京雨泽瑞清生物科技有限公司 一种培养基底的修饰方法及间充质干细胞分离扩增方法
WO2018177554A1 (en) * 2017-03-31 2018-10-04 Ophthorobotics Ag Stimuli-responsive hydrogel and method for a piercing intervention into a mammalian eye
CN109824779B (zh) * 2017-11-23 2023-05-26 中山大学 一种包含IgG的Fc结构域和EB病毒包膜糖蛋白胞外域的融合蛋白
FR3078261B1 (fr) * 2018-02-28 2020-02-07 Universite de Bordeaux Hydrogel pour stimuler la neurotisation, l'osteogenese et l'angiogenese
WO2019225600A1 (ja) * 2018-05-22 2019-11-28 学校法人東京理科大学 ハイドロゲルの評価方法
EP3881072A4 (en) * 2018-11-16 2022-11-09 President And Fellows Of Harvard College MOLECULES AND METHODS FOR ENHANCED IMMUNODETECTION OF SMALL MOLECULES, SUCH AS HISTAMINE
CN110721315B (zh) * 2019-09-18 2023-01-06 温州医科大学 一种fk506缓释纳米胶束的制备方法及其在制备干眼药物上的应用
JP7679939B2 (ja) * 2020-01-28 2025-05-20 国立大学法人 東京大学 再生医療用ゲル材料
FR3110838B1 (fr) * 2020-05-28 2022-06-24 Commissariat Energie Atomique Complexe immunomodulateur et ses applications pour la thérapie
EP3919091A1 (en) * 2020-06-05 2021-12-08 Albert-Ludwigs-Universität Freiburg Bioink for reversibly forming a hydrogel by light
CN112933293B (zh) * 2020-11-06 2022-06-10 浙江大学 一种治疗中枢神经损伤的可注射水凝胶及其制备方法
CN114652903A (zh) * 2022-05-06 2022-06-24 上海益思妙医疗器械有限公司 一种快速聚合医用水凝胶及其制备方法
CN115806736B (zh) * 2022-12-29 2024-03-26 中国科学院长春应用化学研究所 一种mmp酶响应的可注射聚氨基酸水凝胶及其制备方法和应用
WO2025184228A1 (en) * 2024-02-26 2025-09-04 Smartweave, Inc. Smart customizable therapeutic mechanisms and systems for tissue regeneration and growth

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5310903A (en) 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5525610A (en) 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
WO2001044307A2 (en) 1999-11-15 2001-06-21 Biocure, Inc. Degradable poly(vinyl alcohol) hydrogels
US7112668B2 (en) * 2001-01-23 2006-09-26 Curagen Corporation Polypeptides and nucleic acids encoded thereby
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
EP1648900A4 (en) 2003-07-11 2010-02-10 Ariad Pharma Inc PHOSPHORUS MACROCYCLES
US20070167354A1 (en) 2003-08-28 2007-07-19 Kennedy Chad E Hydrogels for modulating cell migration and matrix deposition
JP5219030B2 (ja) 2005-11-24 2013-06-26 満 明石 刺激応答性分解ゲル
US8586086B2 (en) 2008-05-29 2013-11-19 Politecnico Di Milano Hydrogel capable of containing and conveying cells
CA2726949A1 (en) 2008-06-06 2009-12-10 Eth Zuerich Stimuli-responsive hydrogel
WO2010068728A2 (en) 2008-12-11 2010-06-17 The Brigham And Women's Hospital, Inc. Engineering functional tissue from cultured cells

Also Published As

Publication number Publication date
WO2012065751A1 (en) 2012-05-24
US8980278B2 (en) 2015-03-17
EP2648758A1 (en) 2013-10-16
EP2455104A1 (en) 2012-05-23
RU2013127669A (ru) 2014-12-27
CN103249433A (zh) 2013-08-14
JP2013544248A (ja) 2013-12-12
ES2423798T3 (es) 2013-09-24
EP2455104A8 (en) 2012-11-14
EP2455104B1 (en) 2013-07-17
DK2455104T3 (da) 2013-10-14
US20130315996A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
DK3342786T3 (en) Anti-dll3-antistof
EP2566479A4 (en) AZA-INDAZOLES
AP2012006360A0 (en) 5-Alkynyl-pyrimidines
AP2012006640A0 (en) New aminopyrazoloquinazolines
EP2640189A4 (en) 3-deutero-pomalidomide
DK3466977T3 (en) Anti-vla-4-antistoffer
EP2641891A4 (en) PKC ACTIVATOR-
GB201001760D0 (en) Dipenser
GB201001385D0 (en) Cable-tidies
EP2588088A4 (en) SOLID SHAPES
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
AU4937P (en) FlatinsulGL Myoporum insulare
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
AU4536P (en) TB01 Tibouchina urvilleana
GB201015314D0 (en) Improved fly-hook
PL392421A1 (pl) Kształtownik
GB201003529D0 (en) eezy one
AU335150S (en) Wedge
GB201000765D0 (en) Koolkilt
GB201002159D0 (en) Riingtones
GB201002748D0 (en) Under-brella
GB201000020D0 (en) Velcrose
GB201001976D0 (en) Clipperon
GB201000880D0 (en) Kombbi